Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

PureTech (PRTC) Share News

TOP NEWS: Retail pair and under-pressure Vistry booted out of FTSE 100

4th Dec 2024 18:15

(Alliance News) - Frasers Group PLC has been relegated from the FTSE 100 index in its latest quarterly shuffle alongside two constituent peers, housebuilder Vistry Group PLC and variety goods retailer B&M European Value Retail SA. Read More

PureTech Health investigates IPF disease burden amid treatment testing

9th Oct 2024 10:03

(Alliance News) - PureTech Health PLC on Wednesday said a new patient survey for people with idiopathic pulmonary fibrosis has provided new insights into disease burden and patient experience. Read More

PureTech Health celebrates KarXT approval by FDA for schizophrenia

27th Sep 2024 11:30

(Alliance News) - PureTech Health PLC on Friday said KarXT has received US Food & Drug Administration approval for treating schizophrenia. Read More

LONDON MARKET OPEN: Indices green ahead of Fed inflation gauge

27th Sep 2024 09:09

(Alliance News) - Stock prices in London opened somewhat higher on Friday, as investors wait for the US personal consumption expenditure data, plus various European consumer price and confidence readings. Read More

LONDON BRIEFING: FTSE 100 called up, Merchants Trust beats benchmark

27th Sep 2024 07:59

(Alliance News) - European stocks were called to open higher on Friday, ahead of US personal consumption expenditure and other important US data. Read More

IN BRIEF: PureTech's Vor in promising findings in cancer trial

6th Sep 2024 18:07

PureTech Health PLC - Boston, Massachusetts-based biotechnology company - Founded entity Vor Bio, a clinical stage cell and genome engineering company, has received new clinical data from ongoing Phase 1/2 VBP101 study. The study looks at patients with relapsed or refractory acute myeloid leukaemia receiving trem-cel followed by the Mylotarg drug. Recent data demonstrated reliable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic window, and early evidence of patient benefit. Read More

LONDON MARKET OPEN: Stocks stay red as investors prep for US jobs

6th Sep 2024 08:35

(Alliance News) - Stock prices in London opened lower on Friday, as the market prepares for jobs data from the US following an ADP report on Thursday. Read More

LONDON BRIEFING: Stocks seen red as eurozone GDP looms

6th Sep 2024 07:42

(Alliance News) - Stocks were called lower on Friday, joining peers in the US and Asia, ahead of a GDP print from the eurozone later in the day, and following a data-heavy week globally. Read More

CORRECT (Aug 28): PureTech Health loss widens and revenue falls

29th Aug 2024 14:51

(Correcting PureTech Health PLC half-year revenue and pretax loss.) Read More

PureTech Health loss widens and revenue falls amid AGM concerns

28th Aug 2024 09:28

(Alliance News) - PureTech Health PLC on Wednesday reported a widened loss and lower revenue, as it attempted to address shareholder concerns voiced at its June annual general meeting. Read More

UK earnings, trading statements calendar - next 7 days

21st Aug 2024 14:20

UK earnings, trading statements calendar - next 7 days

19th Aug 2024 14:20

EARNINGS AND TRADING: PureTech seals tender offer; HL bid questioned

24th Jun 2024 19:46

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More

IN BRIEF: PureTech's Ankili to be acquired by Virtual Therapeutics

29th May 2024 21:30

PureTech Health PLC - London-listed Biotech company headquartered in Boston - Says Tuesday that founded entity, Ankili Inc, a game developer focusing on improving mental health, will merge with Virtual Therapeutics Corp, a Boston-based digital therapeutics company. As of May 7, PureTech owned over 12.5 million of Ankili common stock. Read More

PureTech-founded Vedanta begins trials for VE303 colonic bacteria drug

21st May 2024 14:07

(Alliance News) - PureTech Health PLC on Tuesday said that a company it founded and in which it maintains a stake had begun trials of a new treatment for clostridioides difficile infection, in the hopes of moving toward regulatory approval. Read More

IN BRIEF: PureTech Health launches USD100 million buyback programme

20th May 2024 09:03

PureTech Health PLC - London-based biotherapeutics company - Launches tender offer to repurchase shares for a maximum consideration of USD100 million. The offer, set to run until June 18, will be for up to 33.5 million shares, around 12% of PureTech's share capital, at a fixed price of 250 pence each. Read More

FTSE 100 Latest

Value9,297.58

Change72.19